US-based cancer care technology developer Carevive Systems has raised an amount indicated by a securities filing to be $15m, in a series C round featuring corporate investors Debiopharm and Philips.
Investment firm Cerner Capital, venture capital firm HLM Venture Partners and VC investment platform LRVHealth also took part in the round along with Carevive’s co-founder and CEO, Madelyn Trupkin Herzfeld.
Biopharmaceutical company Debiopharm and electronics and medical device producer Philips participated through subsidiaries Debiopharm Innovation Fund and Philips Health Technology Ventures respectively.
Founded in 2013, Carevive has developed software that can be integrated into electronic medical record systems to assist oncology care by helping doctors devise personalised care plans for each patient and monitoring their progress at home.
Rich Wilmot, head of Philips Health Technology Ventures said: “We partner with innovative companies with complementary strengths, as we aim to provide our customers with integrated solutions to help them to deliver on the Quadruple Aim of healthcare: improved patient experience, better health outcomes, improved staff experience and lower cost of care.
“Carevive’s suite of patient engagement and clinical cancer care management technologies are very promising and we look forward to working with the company to further improve patient care.”
The latest round comes in the wake of a $7.2m series B in 2016 that included HLM Venture Partners and LRVHealth (then known as Long River Ventures). Carevive has not disclosed details of earlier funding.
